We selected EGFR-mutant NSCLC cells with activating mutations (deletion of exon 19) and with acquired resistance (T790M mutation in EGFR and MEK/MAPK cascade inactivation). This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.